Evidence map›Paper›PMID 31660790›Full record

ArticleLupus2019

Does SLE widen or narrow race/ethnic disparities in the risk of five co-morbid conditions? Evidence from a community-based outpatient care system.

T Falasinnu, Y Chaichian, J Li, S Chung, B E Waitzfelder, S P Fortmann, L Palaniappan, J F Simard

Open access · greenAbstract read
In one paragraph

Article in Lupus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

T FalasinnuDepartment of Health Research and Policy, Stanford University School of Medicine, Palo Alto, CA, USA.ORCID https://orcid.org/0000-0002-9580-4743
Y ChaichianDivision of Immunology and Rheumatology, Department of Medicine, Stanford University, Palo Alto, CA, USA.
J LiPalo Alto Medical Foundation Research Institute, Palo Alto, CA, USA.
S ChungPalo Alto Medical Foundation Research Institute, Palo Alto, CA, USA.
B E WaitzfelderCenter for Health Research, Kaiser Permanente Hawaii, HI, USA.
S P FortmannDepartment of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
L Palaniappan
J F SimardDepartment of Health Research and Policy, Stanford University School of Medicine, Palo Alto, CA, USA.
Stanford University · USPalo Alto Institute · USKaiser Permanente Center for Health Research · US

Funding

Cardiovascular Disease Among Asians and Pacific Islanders (CASPER)R01HL126172 · NHLBI · KAISER FOUNDATION RESEARCH INSTITUTE · PI FORTMANN, STEPHEN PAUL, PALANIAPPAN, LATHA P · 2015 to 2018
$3.0M
META - Mentor, Educate, Train, Advocate: Patient Oriented Researchers in Cardiometabolic DiseaseK24HL150476 · NHLBI · STANFORD UNIVERSITY · PI Latha P Palaniappan · 2020 to 2026
$846k
NHLBI NIH HHS K24 HL150476NHLBI NIH HHS R01 HL126172
6 · The paper itself

Abstract

objectiveThe heterogeneous spectrum of systemic lupus erythematosus (SLE) often presents with secondary complications such as cardiovascular disease (CVD), infections and neoplasms. Our study assessed whether the presence of SLE independently increases or reduces the disparities, accounting for the already higher risk of these outcomes among racial/ethnic minority groups without SLE.

methodsWe defined a cohort using electronic health records data (2005-2016) from a mixed-payer community-based outpatient setting in California serving patients of diverse racial/ethnic backgrounds. The eligible population included adult patients with SLE and matched non-SLE patients (≥18 years old). SLE was the primary exposure. The following outcomes were identified: pneumonia, other infections, CVD and neoplasms. For each racial/ethnic group, we calculated the proportion of incident co-morbidities by SLE exposure, followed by logistic regression for each outcome with SLE as the exposure. We evaluated interaction on the additive and multiplicative scales by calculating the relative excess risk due to interaction and estimating the cross-product term in each model.

resultsWe identified 1036 SLE cases and 8875 controls. The incidence for all outcomes was higher among the SLE exposed. We found little difference in the odds of the outcomes associated with SLE across racial/ethnic groups, even after multivariable adjustment. This finding was consistent on the multiplicative and additive scales.

conclusionWe demonstrated that SLE status does not independently confer substantial interaction or heterogeneity by race/ethnicity toward the risk of pneumonia, other infections, CVD or neoplasms. Further studies in larger datasets are necessary to validate this novel finding.

Indexed as

AdolescentAdultAgedAmbulatory CareCaliforniaCardiovascular DiseasesCohort StudiesComorbidityEthnicityFemaleHumansIncidenceLogistic ModelsLupus Erythematosus, SystemicMaleMiddle AgedCardiovascular diseasesystemic lupus erythematosusthrombosis

Identifiers

PMID31660790
PMCPMC8459796
OpenAlexW2982451889

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.